Evaluation of Biochemical Recurrence-free Survival after Radical Prostatectomy by Cancer of the Prostate Risk Assessment Post-Surgical (CAPRA-S) Score

Abstract

Like several previously published prognostic instruments,

External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score for Prediction of Disease Recurrence after Radical Prostatectomy

“…We performed the CAPRA-S score of 203 patients who underwent RP in prostate cancer. We found significant correlation with high risk scores and BCR as stated in the literature [4, 8, 9]. …”

Does surgical delay for radical prostatectomy affect patient pathological outcome? A retrospective analysis from a Canadian cohort

“…15 Adverse pathological outcome was measured by the Cancer of the Prostate Risk Assessment (CAPRA-S) score, which has been well-documented to correlate with BCR, and cancer specific survival (CSS). [16][17][18][19][20][21][22] CAPRA-S score includes initial PSA, pathological Gleason, extracapsular extension (ECE), surgical margins (SM) status, seminal vesicle invasion (SVI), and lymph node (LN) status if lymph node dissection was done. Patients, who did not have LN dissection were considered LN-negative to calculate CAPRA-S score.…”

Australian validation of the Cancer of the Prostate Risk Assessment Post‐Surgical score to predict biochemical recurrence after radical prostatectomy

“…Our findings add to the small but growing literature validating CAPRA‐S across different settings. To date validation studies of unmodified CAPRA‐S have been undertaken in a multi‐institutional cohort from the USA, a highly specialized single institution series in Europe and single surgeon/institution series in Korea and Turkey, and now a multi‐institutional cohort from a large community based PCa registry in Australia (Table S2 summarizes these studies). Each has shown CAPRA‐S to have adequate discrimination, with C‐index values for 5‐year BRFP ranging from 0.73 to 0.87, and generally good calibration across the range of scores.…”

“…Sub‐scores are assigned to each of the post‐surgical indicators based on severity levels and summed to derive the final CAPRA‐S score. Since its development in 2011, the CAPRA‐S score has been validated in a multi‐institutional cohort in the USA, a large single‐institute cohort in Germany and smaller single surgeon/institute series in Korea and Turkey …”

“…Since its development in 2011, the CAPRA-S score has been validated in a multi-institutional cohort in the USA, 8 a large single-institute cohort in Germany 9 and smaller single surgeon/institute series in Korea 10,11 and Turkey. 12 Experts suggested that risk assessment tools be assessed within the settings in which they will be used. 13 Previous validation of CAPRA-S undertaken in the USA 8 may not be applicable in the Australian context given the high proportion of African-American men who have more aggressive PCa.…”